Feb 8, 2024 | Press Releases
LOS ANGELES, CA, Feb. 08, 2024 — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and...
Feb 7, 2024 | Press Releases
European Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for EU protocol assistance, marketing authorization applications,...
Feb 5, 2024 | Press Releases
LOS ANGELES, CA, Feb. 05, 2024 — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and...
Feb 5, 2024 | Press Releases
LOS ANGELES, Feb. 05, 2024 — Immix Biopharma, Inc. (Nasdaq: IMMX) (the “Company”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that it intends to offer and sell shares of its common...
Jan 24, 2024 | Press Releases
LOS ANGELES, CA, Jan. 24, 2024 — Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today...
Jan 4, 2024 | Press Releases
Dr. Sanchorawala co-authored landmark study of daratumumab (DARZALEX®) in AL Amyloidosis published in The New England Journal of Medicine, 2021 that led to it becoming a first-line standard of careLOS ANGELES, Jan. 04, 2024 — Immix Biopharma, Inc....